Skip to main content
. 2021 Jul 13;297(2):100947. doi: 10.1016/j.jbc.2021.100947

Figure 1.

Figure 1

Screen results and validation.A, Z-scores and enrichment fold-changes of retroviral insertions within the gene bodies of indicated genes after selection in N2B27 + CHIR + Puromycin. In blue are pluripotent network TFs. Red labels previously described differentiation driver genes and orange novel candidates. B–D and F, Nanog>GFP intensities after switching from 2iLIF to N2B27 + CHIR + bFGF for 3 days (B–D) or as indicated in panel F of indicated genotypes. Dashed lines indicate the thresholds for quantifications presented in Fig. S1, D and F. E, TFE3 immunofluorescence in Nmt1−/− and WT mESCs in 2iLIF. Nuclei were counterstained with Hoechst. G, scatterplot of log2 fold-changes (FC) in gene expression of indicated contrasts. Green labels post-implantation epiblast (postEPI)-specific and red pre-implantation epiblast (preEPI)-specific genes (56). 2iLIF, N2B27 containing LIF, CHIR, and PD0325901; bFGF, basic FGF; CHIR, CHIR99021; mESCs, mouse embryonic stem cells; N2B27, chemically defined medium.